JAMP Pharma

Your pharmacy’s generic partner.

We are committed to continuously improving the supply and access to affordable medicines for all Canadians.

Proudly Canadian, we provide continuous access to high quality and affordable generic products: this is our promise.

Alvotech and JAMP Pharma announce receipt of marketing authorization for PrJamtekiTM (AVT04), the first biosimilar of Stelara® (ustekinumab)

PrJamtekiTM is the second biosimilar developed under this partnership that receives marketing authorization in Canada. REYKJAVIK, ICELAND & BOUCHERVILLE, QC (November 9, 2023) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and JAMP Pharma Group (“JAMP…
November 14, 2023
BIOJAMP, New launches, News and events, Press release
JAMP Pharma Group receives Health Canada approval for Pr JAMP Dapagliflozin, a new generic alternative for the treatment of type 2 diabetes

The JAMP Pharma Group has received authorization to market Dapagliflozin, offering a more affordable alternative to the reference product Forxiga® (marketed by AstraZeneca Canada Inc.). The JAMP Pharma Group, a leader in product launches1, is expending its product line for the treatment of diabetes, bringing it closer to achieving its goal…
May 15, 2023
New launches, Press release
JAMP Pharma Group receives Health Canada approval for PrJAMP Sitagliptin, a new generic alternative for the treatment of type 2 diabetes

The JAMP Pharma Group has received authorization to market Sitagliptin, offering a more affordable alternative to the reference product Januvia® (marketed by Merck Canada Inc.). The JAMP Pharma Group, a leader in product launches1, is expanding its product line for the treatment of diabetes, bringing it closer to achieving its…
January 6, 2023
Uncategorized

¹ Pharmaceutical manufacturers with the highest volume of prescriptions reported in Canada from January to August 2021. Based in part on data obtained under licence from IQVIA Solutions Canada Inc., concerning the following information service: CompuScript, January to August 2021. All Rights Reserved. The statement expressed herein is not necessarily that of IQVIA Solutions Canada Inc. or any of its affiliated or subsidiary entities.

² Pharmaceutical manufacturers with the highest volume of product launches in Canada from 2016 to 2022. Based in part on data obtained under licence from IQVIA Solutions Canada Inc., concerning the following information service: Canadian Drug Store and Hospital Audit, moving annual total from January to December 2016 to 2022. All Rights Reserved. The statement expressed herein is not necessarily that of IQVIA Solutions Canada Inc. or any of its affiliated or subsidiary entities.

³ Proportion of complete orders delivered, Internal data Groupe JAMP Pharma, OTIF from January 1st 2022 to December 15th 2022.

JAMP Pharma

Proudly Canadian, we provide continuous access to high quality and affordable generic products: this is our promise.

Alvotech and JAMP Pharma announce receipt of marketing authorization for PrJamtekiTM (AVT04), the first biosimilar of Stelara® (ustekinumab)

JAMP Pharma Group receives Health Canada approval for Pr JAMP Dapagliflozin, a new generic alternative for the treatment of type 2 diabetes

JAMP Pharma Group receives Health Canada approval for PrJAMP Sitagliptin, a new generic alternative for the treatment of type 2 diabetes